Scholar Rock Holding Corporation – NASDAQ:SRRK
Scholar Rock Holding stock price today
$30.72
-13.74
-30.9%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 3 minutes
Scholar Rock Holding stock price monthly change
+388.57%
month
Scholar Rock Holding stock price quarterly change
+388.57%
quarter
Scholar Rock Holding stock price yearly change
+130.24%
year
Scholar Rock Holding key metrics
Market Cap | 4.13B |
Enterprise value | 444.80M |
P/E | -3.37 |
EV/Sales | 6.70 |
EV/EBITDA | -3.30 |
Price/Sales | 7.21 |
Price/Book | 1.83 |
PEG ratio | -0.09 |
EPS | -2.2 |
Revenue | N/A |
EBITDA | -184.65M |
Income | -183.26M |
Revenue Q/Q | N/A |
Revenue Y/Y | -64.87% |
Profit margin | -202.61% |
Oper. margin | -202.41% |
Gross margin | 0% |
EBIT margin | -202.41% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeScholar Rock Holding stock price history
Scholar Rock Holding stock forecast
Scholar Rock Holding financial statements
Average Price Target
$39.67
Potential upside: 29.12%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -37.92M | |
|---|---|---|---|
| Sep 2023 | 0 | -42.35M | |
| Dec 2023 | 11.66M | -46.12M | -395.59% |
| Mar 2024 | 0 | -56.85M |
| Jun 2023 | 284900000 | 82.39M | 28.92% |
|---|---|---|---|
| Sep 2023 | 250689000 | 83.02M | 33.12% |
| Dec 2023 | 311035000 | 85.81M | 27.59% |
| Mar 2024 | 267285000 | 84.51M | 31.62% |
| Jun 2023 | -32.55M | -15.24M | 4.68M |
|---|---|---|---|
| Sep 2023 | -32.27M | -8.47M | 280K |
| Dec 2023 | -37.34M | -25.12M | 96.52M |
| Mar 2024 | -49.78M | 33.38M | 6.52M |
Scholar Rock Holding alternative data
| Aug 2023 | 114 |
|---|---|
| Sep 2023 | 114 |
| Oct 2023 | 114 |
| Nov 2023 | 114 |
| Dec 2023 | 114 |
| Jan 2024 | 114 |
| Feb 2024 | 114 |
| Mar 2024 | 150 |
| Apr 2024 | 150 |
| May 2024 | 150 |
| Jun 2024 | 150 |
| Jul 2024 | 150 |
Scholar Rock Holding other data
83.43%
+2.38%
of SRRK is owned by hedge funds
30.62M
+896.68K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 15671 |
| Feb 2024 | 0 | 26110 |
| Jun 2024 | 0 | 20773 |
| Aug 2024 | 0 | 1451 |
| Sep 2024 | 0 | 1936 |
| Oct 2024 | 0 | 1558515 |
| Nov 2024 | 0 | 420058 |
| Dec 2024 | 0 | 1600000 |
| Quarter | Transcript |
|---|---|
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2020 12 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Nagesh K. Mahanthappa MBA, Ph.D. (1965) Interim Chief Executive Officer & Director | $1,370,000 |
Mr. Edward H. Myles M.B.A., MBA (1972) Chief Financial Officer & Head of Bus. Operations | $660,510 |
| Dr. Gregory John Carven Ph.D. (1976) Chief Scientific Officer | $551,330 |
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Scholar Rock: Solid Data And Good Prospects
Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look
Scholar Rock: The Market Isn't Enthusiastic Despite Decent Clinical Data
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of Scholar Rock Holding stock today?
One share of Scholar Rock Holding stock can currently be purchased for approximately $30.72.
-
When is Scholar Rock Holding's next earnings date?
Unfortunately, Scholar Rock Holding's (SRRK) next earnings date is currently unknown.
-
Does Scholar Rock Holding pay dividends?
No, Scholar Rock Holding does not pay dividends.
-
How much money does Scholar Rock Holding make?
Scholar Rock Holding has a market capitalization of 4.13B.
-
What is Scholar Rock Holding's stock symbol?
Scholar Rock Holding Corporation is traded on the NASDAQ under the ticker symbol "SRRK".
-
What is Scholar Rock Holding's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Scholar Rock Holding?
Shares of Scholar Rock Holding can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Scholar Rock Holding's key executives?
Scholar Rock Holding's management team includes the following people:
- Dr. Nagesh K. Mahanthappa MBA, Ph.D. Interim Chief Executive Officer & Director(age: 60, pay: $1,370,000)
- Mr. Edward H. Myles M.B.A., MBA Chief Financial Officer & Head of Bus. Operations(age: 53, pay: $660,510)
- Dr. Gregory John Carven Ph.D. Chief Scientific Officer(age: 49, pay: $551,330)
-
How many employees does Scholar Rock Holding have?
As Jul 2024, Scholar Rock Holding employs 150 workers.
-
When Scholar Rock Holding went public?
Scholar Rock Holding Corporation is publicly traded company for more then 7 years since IPO on 25 May 2018.
-
What is Scholar Rock Holding's official website?
The official website for Scholar Rock Holding is scholarrock.com.
-
Where are Scholar Rock Holding's headquarters?
Scholar Rock Holding is headquartered at 301 Binney Street, Cambridge, MA.
-
How can i contact Scholar Rock Holding?
Scholar Rock Holding's mailing address is 301 Binney Street, Cambridge, MA and company can be reached via phone at 857 259 3860.
-
What is Scholar Rock Holding stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Scholar Rock Holding in the last 12 months, the avarage price target is $39.67. The average price target represents a 29.12% change from the last price of $30.72.
Scholar Rock Holding company profile:
Scholar Rock Holding Corporation
scholarrock.comExchange:
NASDAQ
Full time employees:
150
Industry:
Biotechnology
Sector:
Healthcare
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
301 Binney Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001727196
ISIN: US80706P1030
CUSIP: 80706P103
